A Cost Per Responder Analysis of Secukinumab Vs Adalimumab Based on A Matching-Adjusted Indirect Comparison For The Treatment of Ankylosing Spondylitis From A German Payer Perspective
Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.09.1108
https://www.valueinhealthjournal.com/article/S1098-3015(16)32474-3/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1038
First Page :
A537
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32474-3&doi=10.1016/j.jval.2016.09.1108